Detailed Coverage

Anthem Biosciences Q1 Results

Anthem Biosciences reported consolidated revenue of ₹418 crore for the first quarter of FY27.
The company achieved a strong EBITDA margin of 39.6% and a PAT margin of 27.1%.

Reader Takeaway: Strong margins maintained; monitor annual growth and Semaglutide API approval.

What just happened

Anthem Biosciences announced its Q1 FY27 financial results. Consolidated revenue stood at ₹418 crore. The CRDMO segment contributed 81.5% to revenue (₹341 crore), while Specialty Ingredients accounted for 18.5% (₹78 crore).

The company reported an EBITDA of ₹176 crore and a Profit After Tax (PAT) of ₹120 crore.

Why this matters

Despite a soft Q1 attributed to delivery timing shifts, the company maintained robust profitability with impressive margins. This indicates operational efficiency and cost management, which are crucial for sustained investor confidence in a project-based business.

The strong net cash position of ₹1,720 crore provides financial flexibility for ongoing and future investments.

The backstory

Anthem Biosciences operates in the Contract Research, Development, and Manufacturing Organization (CRDMO) and Specialty Ingredients sectors. The CRDMO business is known for its lumpy revenue patterns due to the nature of project timelines and raw material procurement.

The company has been investing in expanding its capacities, including Unit 4, which is slated for commissioning by the end of FY28.

What changes now

Investors are advised to focus on the company's annual performance trajectory rather than short-term quarterly fluctuations. The management's reaffirmation of long-term growth aligns with historical trends.

Near-term catalysts include awaiting CDSCO approval for the Semaglutide API, which could open new revenue streams in the coming quarters.

Risks to watch

Regulatory approval timelines for new products like the Semaglutide API are critical. The "lumpy" nature of the CRDMO business can lead to significant revenue variations between quarters.

Capacity utilization across different units needs to be monitored, especially as Unit 3 ramps up and Unit 4 construction progresses.

Peer comparison

As Anthem Biosciences focuses on CRDMO and API manufacturing, its peers include other Indian pharmaceutical companies with similar contract manufacturing and R&D service offerings. Companies like Laurus Labs and Divi's Laboratories also operate in related segments, emphasizing integrated services and capacity expansion.

Context metrics (time-bound)

• Q1 FY27 Revenue: ₹418 crore.
• EBITDA Margin: 39.6%.
• PAT Margin: 27.1%.
• Net Cash: ₹1,720 crore.
• Capex planned for FY27: ₹700 crore.
• Unit 4 commissioning: Expected by end of FY28.
• Order book visibility: 60% for the full year.

What to track next

Investors should closely watch the CDSCO approval status for the Semaglutide API. Progress on Unit 4's construction and its eventual commissioning will be key for future growth. Monitoring quarterly revenue trends and margin stability will also be important.